Stay updated on Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.

Latest updates to the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 has been added and Revision: v3.4.1 removed; the government funding/operating status notice was deleted.SummaryDifference0.4%

- Check20 days agoChange DetectedA site-wide notice about a lapse in government funding and NIH operations is now displayed, and the page shows a new revision tag (v3.4.1) replacing the previous v3.4.0.SummaryDifference0.5%

- Check28 days agoChange DetectedThe updates are minor UI and text changes: a glossary display was added, capitalization adjustments to QC-related labels, and the revision note updated from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 appears on the page, replacing v3.3.3. This is a minor site version update and does not alter study details or page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedA new Locations section appears with California listed as a site. The footer revision note updates to Revision: v3.3.3 and the HHS Vulnerability Disclosure link has been removed.SummaryDifference0.2%

- Check85 days agoChange DetectedThe footer revision label updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.